Colicchia, A. and Fabian, D. and Grabenhofer, L. and Grössmann-Waniek, N. and Malíková, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B. Decision Support Document for the Austrian Appraisal Board 002.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Geiger-Gritsch, S. and Grössmann-Waniek, N. and Malikova, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease. Decision Support Document for the Austrian Appraisal Board 003.

Goetz, G. and Jeindl, R. and Yoldas, B. and Colicchia, A. (2026): Genetic Testing in Austria. Part A: Application Fields and Prioritisation Criteria. HTA-Projektbericht 176a.

Colicchia, A. and Goetz, G. and Geiger-Gritsch, S. (2026): Genetic Testing in Austria. Part C: Detection of PIK3CA/AKT1/PTEN/ESR1 genetic alterations in HR+/HER2– breast cancer. HTA-Projektbericht 176c.